Charles River Laboratories International (CRL) EPS (Basic) (2009 - 2025)

Charles River Laboratories International (CRL) has reported EPS (Basic) for 16 consecutive years, with -$5.58 the latest figure, recorded in Q4 2025.

• In Q4 2025, EPS (Basic) fell 32.91% year-over-year to -$5.58; the TTM figure through Dec 2025 stood at -$2.91 (down 1553.11% YoY), while the FY2025 annual figure was -$2.91, down 1553.11% from the prior year.
• EPS (Basic) came in at -$5.58 for Q4 2025 at Charles River Laboratories International, down from $1.11 in the prior quarter.
• The five-year high for EPS (Basic) was $3.72 in Q4 2022, with the low at -$5.58 in Q4 2025.
• Average EPS (Basic) over 5 years is $1.21, with a median of $1.77 recorded in 2021.
• Across the five-year window, EPS (Basic) surged 47.0% in 2022 and plunged 214.95% in 2024, its largest moves.
• Year by year, EPS (Basic) stood at $2.78 in 2021, then jumped by 33.86% to $3.72 in 2022, then retreated by 1.87% to $3.65 in 2023, then slumped by 214.95% to -$4.2 in 2024, then sank by 32.91% to -$5.58 in 2025.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$5.58, $1.11, and $1.06 for Q4 2025, Q3 2025, and Q2 2025 respectively.